Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
| Autor: | Gutzmer, R., Rivoltini, L., Levchenko, E., Testori, A., Utikal, J., Ascierto, P.A., Demidov, L., Grob, J.J., Ridolfi, R., Schadendorf, D., Queirolo, P., Santoro, A., Loquai, C., Dreno, B., Hauschild, A., Schultz, E., Lesimple, T.P., Vanhoutte, N., Salaun, B., Gillet, M., Jarnjak, S., De Sousa Alves, P.M., Louahed, J., Brichard, V.G., Lehmann, F.F. |
|---|---|
| Zdroj: | In ESMO Open 2016 1(4) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|